Deliverable: Transcripts

Objectives:

n      Assess the level of awareness and anticipation for MedImmune/AstraZeneca’s Numax® and its potential use in the prevention of respiratory syncytial virus (RSV)

n      Elicit expert feedback on Numax

n      Determine potential to displace Synagis

Products Highlighted:

n      Numax® (MEDI-524), AstraZeneca, MedImmune

n      Synagis® (palivizumab), AstraZeneca, MedImmune

Topics:

n      Level of unmet need in RSV prophylaxis

n      Likelihood of approval

n      Clinical and commercial potential

n      Patient selection  

n      Potential for displacement of Synagis

n      Price sensitivity

Selected Quotes:

n      It is relatively easy to administer, reimbursement is fair, side effects are rare, and is efficacious in reducing hospitalization, serious illness, and fatal infection  

n      We have to complete a form for the home nursing agency and usually another form for insurance pre-authorization

n      However, cost, safety, efficacy, dosing and administration are all questions in my mind about this new agent

n      The results of this randomized double blind multicenter study comparing synagis to numax are highly …

n      We would likely need to know a lot more about how this data is analyzed to see what the individual data truly meant

Screening Criteria:

n      Board-certified in pediatrics and/or neonatology

n      Based in U.S

n      2-30 years of practice

n      Significant clinical experience with Synagis for RSV prophylaxis

n      Publication history in pediatric/neonatal infectious disease

n      Clinical trial participation in this domain

Representative Institutions:

n      Baylor College of Medicine

n      Hasbro Children’s Hospital

n      Mattel Children’s Hospital UCLA

n      Meharry Medical College

n      St. John’s Hospital

n      SUNY Upstate Medical University

n      University of Florida